Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Terminated × Solid Cancer × Clear all

Phase

Status

Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 107 Neoplasms 86 Breast Neoplasms 80 Leukemia, Myeloid, Acute 68 Multiple Myeloma 67 Melanoma 65 Neoplasm Metastasis 62 Recurrence 59 Ovarian Neoplasms 52 Colorectal Neoplasms 50 Prostatic Neoplasms 48 Lymphoma 46 Leukemia 45 Lymphoma, Non-Hodgkin 44 Lung Neoplasms 42 Pancreatic Neoplasms 41 Leukemia, Lymphocytic, Chronic, B-Cell 36 Precursor Cell Lymphoblastic Leukemia-Lymphoma 32 Myelodysplastic Syndromes 32 Carcinoma, Renal Cell 29 Squamous Cell Carcinoma of Head and Neck 28 Carcinoma, Hepatocellular 28 Triple Negative Breast Neoplasms 25 Glioblastoma 25 Lymphoma, Large B-Cell, Diffuse 24 Brain Neoplasms 24 Stomach Neoplasms 23 Lymphoma, Follicular 21 Small Cell Lung Carcinoma 20 Urinary Bladder Neoplasms 19

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡